44 results about "Coiled coil" patented technology

Myocilin-binding agents including antibodies and antigen binding fragments thereof and fusion proteins that immunospecifically bind the coiled-coil domain of myocilin but do not bind to misfolded myocilin are provided herein. The disclosed antibodies and antigen binding fragments and fusion proteins are useful for the detection and extraction of natively folded myocilin from a sample.

Myocilin-binding agents including antibodies and antigen binding fragments thereof and fusion proteins that immunospecifically bind the coiled-coil domain of myocilin but do not bind to misfolded myocilin are provided herein. The disclosed antibodies and antigen binding fragments and fusion proteins are useful for the detection and extraction of natively folded myocilin from a sample.

The present disclosure provides compositions and methods comprising a selective inhibitor of Rho-related coiled-coil kinase 2 (ROCK2) for use in the treatment of viral infections, particularly coronavirus infections such as SARS-CoV-2, and in the treatment of sequelae caused by the viral infections, including sequelae caused by coronavirus infections.

Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.

The present invention pertains to specific bioparticules at the surface of which are expressed multimeric protein. The bioparticles according to the present invention comprise an envelope consisting of a plasma membrane; and at least one type I or II transmembrane fusion protein anchored in said membrane, said fusion protein comprising successively a) a first monomer of a multimeric protein of interest, b) a coiled-coil domain or oligomerization sequence; and c) a domain for anchoring in the plasma membrane, consisting of a transmembrane segment and a cytosolic segment. Fragments a) and b) are exposed at the surface of the bioparticle, and fragment a) is bound to a second monomer of said multimeric protein by means of a bond which is not a peptide bond. The bioparticles according to the present invention can be used in therapy such as immunotherapy. The present invention also pertains to methods for producing such bioparticles.

The present invention relates generally to a plant cell-surface immune receptor engineered to modulate an immune response in a plant, cell or seed, as well as nucleic acid molecules encoding the engineered receptor, and methods of use. In particular, the present invention relates to a plant cell-surface immune receptor into which a coiled-coil (CC) motif is integrated to enhance or modify the plant's immune response, with utility in reducing pathogen infection and improving pathogen resistance.

To provide a combination of proteins that contains a TlpA mutant and can induce substance interaction by heating.SOLUTION: A protein set for inducing substance interaction in a temperature-dependent manner comprises: a protein set comprising a protein having a binding-inducing peptide bound to the N-terminus or C-terminus of the following protein a, the following protein b, and the binding-inducing protein; or a protein set comprising a protein having a binding-inducing peptide bound to the N-terminus or C-terminus of the following protein b, the following protein a, and the binding-inducing protein; a: a protein comprising the whole or a part of a coiled-coil region of a protein having a specific amino acid sequence, and having mutations indicated by E180R and E250R; and b: a protein comprising the whole or a part of a coiled-coil region of a protein having the specific amino acid sequence and having mutations indicated by R179E and R251E.SELECTED DRAWING: None

The present invention relates to a method for treating primary ciliary dyskinesia (PCD) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing skipping of exon 3 of a Coil Spiral Domain Protein 40 (CCDC40) precursor mRNA. Also provided is a composition comprising the splicing modifier and uses thereof.

The present invention relates to a hepatitis delta virus (HDV) polypeptide comprising an antigenic domain comprising an amino acid sequence of SEQ ID NO:1 or an amino acid sequence at least 60% identical thereto, wherein said polypeptide (i) is devoid of a coiled-coil domain consisting of the amino acid sequence of SEQ ID NO:2 or an amino acid sequence at least 60% identical thereto; or (ii) further comprises said coiled-coil domain, wherein said coiled-coil domain comprises at least one of the following mutations: (I) the amino acid at position 20 is not tryptophan, and (II) the amino acid at position 50 is not tryptophan. Moreover, the present invention relates to proteins, kits, polynucleotides, host cells, methods, and devices related thereto.

The disclosure is in the field of immunology and oncology, especially for treating, preventing, or inhibiting proliferative diseases, particularly cancer, infectious diseases and disorders associated with dysfunction of TNF cytokines. The disclosure relates to a novel SPD-TNFSF fusion protein including a TNF-superfamily (TNFSF) ligand, or receptor binding domain thereof, fused to a coiled-coil domain of surfactant protein-D (SPD). Also provided a trimeric or multimeric fusion protein including a plurality of SPD-TNFSF fusion proteins. The disclosure also provides an expression vector as mRNA, plasmid or virus including an isolated nucleotide sequence encoding the SPD-TNFSF fusion protein and a cell or a pharmaceutical composition including thereof.

The present invention relates to a lipopeptide building block consisting of (i) a peptide moiety comprising a coiled coil peptide chain segment, wherein said coiled coil peptide chain segment comprises 3 to 8 repeat units, and wherein said repeat unit consists of the sequence IEKKIE-X0 (SEQ ID NO:58), wherein X0 represents an amino acid; and (ii) a lipid moiety comprising the formula LM-Iwherein R1 and R2 are independently C11-15 alkyl, wherein R3 is hydrogen or —C(O)C11-15 alkyl wherein said lipid moiety is linked to said peptide moiety, wherein the wavy line in formula LM-I indicates the linkage site to said peptide moiety, as well as conjugates comprising said lipopeptide building blocks to which antigens are coupled, bundles of such conjugates, synthetic virus-like particles (SVLPs) comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same.

The present application relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of target immune drug for primary liver cancer and application thereof, wherein the combined marker is folate receptor gamma gene FOLR3, stratified protein gene SFN and coiled-coil domain containing 9 gene CCDC9 derived from peripheral blood leukocyte mRNA.The present application performs combined detection based on multiple peripheral blood leukocyte markers, and compared with a single molecular marker, can reduce errors caused by individual expression difference of a single index to some extent, so that the detection result is more accurate.The curative effect prediction model constructed based on detection of peripheral blood leukocyte mRNA level change can specifically recognize and detect in the early stage of tumor formation, has high sensitivity and high specificity, provides an important means for reasonable use of target immune drug for liver cancer patients sensitive or resistant to target immune drug, and has great significance for effective treatment of liver cancer in China.

To provide inhibitors of ROCK1 and / or ROCK2.SOLUTION: The present invention provides methods of inhibiting ROCK1 and / or ROCK2 that are useful for the treatment of disease.SELECTED DRAWING: Figure 1

The invention discloses a self-assembled nanofiber antibacterial peptide based on a coiled spiral structure and a preparation method and application thereof, and belongs to the technical field of biology, and the amino acid sequence is as shown in SEQ ID No.1. The preparation method comprises the following steps: adopting an alpha-spiral heptapeptide repetitive sequence (abcdefg) 4 template, and selecting lysine to provide positive charges at positions b and c; leucine and isoleucine are respectively filled to a position a and a position d to provide intermolecular hydrophobic force, and lysine and glutamic acid are selected to be respectively filled to a position e and a position g to provide intermolecular electrostatic force; the position f of the center of the hydrophilic surface of the polypeptide is filled with tryptophan to optimize the hydrophobicity of the polypeptide, and the sequence is repeated for four times on the basis. The invention further discloses application of the antibacterial peptide in preparation of drugs for treating gram-positive bacteria or / and gram-negative bacteria infectious diseases. The antibacterial peptide disclosed by the invention has relatively strong antibacterial activity and good biocompatibility, and provides an effective technical support for developing a novel antibacterial drug.

Provided herein are compositions of lipid delivery particles used to deliver a payload to a target cell and methods of producing the like. The lipid delivery particles can comprise a coiled-coil peptide pair, plasma membrane recruitment element, lipid membrane, envelope protein, or any combination thereof. The lipid delivery particles can be used to introduce one or more edits in a cell. Disclosed herein, in some aspects, are nucleic acid molecules encoding the same.

Compositions of anti-inflammatory peptides and methods of use thereof are provided. The peptides include N-terminal, palmitoylated peptides covering / derived from a coiled-coil region of CRACR2A. Methods include reducing inflammation and / or inhibiting a STIM1-CRACR2A interaction in a subject in need thereof by administering a composition of the present disclosure. Exemplary compositions include palmitoylated peptides having between about 10 and 20 amino acids.

Disclosed is a multimeric fusion protein and a method for producing the multimeric fusion protein. The method includes expressing in an mammalian cell a nucleic acid coding for an amino acid sequence comprising, in an N-terminal to C-terminal direction, a signal peptide, (optionally) an antigenic peptide, a CH3 domain of human IgG1, a (G-P-P)10 collagen-like domain, and a TNF ligand superfamily extracellular domain, the extracellular domain being devoid of a coiled-coil trimerization motif, and allowing the polypeptides expressed in the mammalian cell from the nucleic acid to at least one of trimerize and hexamerize into one or more multimeric fusion proteins.

This invention relates to the field of underwater adhesive materials, and particularly to an injectable self-healing underwater protein and its uses. The invention provides a fusion protein comprising a mussel byssal protein fragment and a coiled-helical structure fragment. This invention involves genetic recombination of mussel byssal protein and the coiled-helical structure, thereby providing a novel fusion protein that can self-assemble in solution to form a gel material, possessing both the interfacial adhesiveness of mussel byssal protein and the intrinsic adhesiveness of the coiled-helical structure, thus achieving super-strong underwater adhesion.

The invention belongs to the technical field of biological vaccines. The invention particularly relates to a recombinant bacteriophage capable of inducing mucosal immune response and application of the recombinant bacteriophage. Specifically, a pVIII capsid protein is utilized to display a SpyCatcher protein on the surface of an M13 bacteriophage particle (for example, through a pVIII-trimer parallel coiled spiral structure coiled-coil-SpyCatcher structure), and an antigen protein is coupled through SpyCatcher and SpyTag, so that the antigen protein is efficiently displayed on the surface of the bacteriophage, and the recombinant M13 bacteriophage is obtained. The capsid protein of the recombinant M13 bacteriophage can display hundreds of copies of same epitopes, the natural structure on the surface of a pathogen is simulated by the highly dense and highly repeated antigen arrangement mode, a B cell receptor is effectively cross-linked, a strong humoral immune response is induced, and no extra adjuvant is needed.

The present invention provides a CASP9 suicide gene safety switch controlled by a TetOn system and construction thereof. Specifically, the present invention provides a coiled coil-CASP9 fusion protein whose expression is regulated by a tetracycline-inducible system. A dimer or multimer is formed by means of a coiled-coil sequence, so that Caspase-9 has cleavage activity, thereby inducing CAR-T cell apoptosis. The present invention has the effects of reducing adverse reactions and improving safety during CAR-T therapy.

The present invention relates to an antibody or antigen-binding fragment thereof specific for transmembrane and coiled domain family 3 (TMCC3). The invention also relates to a pharmaceutical composition for treating and / or preventing a disease associated with a TMCC3-mediated signal in a subject in need thereof, and a method for detecting TMCC, cancer stem cells or cancer in a sample.

According to the method for rapidly disassembling the winding drum of the coil dividing line uncoiler, the head of the winding drum is connected and locked through a guide chain and a steel wire rope, the winding drum is dragged in the direction of a stepping beam through a coil feeding trolley, and the uncoiler is dragged in the direction of a transmission side opposite to the direction of the stepping beam through a hydraulic rod of an automatic centering cpc. The winding drum replacing device has the beneficial effects that the operation time for replacing the winding drum can be saved, and the labor intensity is greatly reduced; the situation that quick-wear parts of the winding drum cannot be replaced under the condition that the rectangular pyramid sleeve and the sector plate cannot be detached independently is avoided, the maintenance cost of spare parts is saved, the situation that the repairing period is long when the winding drum of the uncoiler and the speed reducer are detached together is avoided, the production limitation of some steel types with high additional value and difficulty in rolling steel is eliminated, and the production benefit is improved.

This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:T1-f0-g0-a1-b1-c1-d1-e1-f1-g1-a2-b2-c2-d2-e2-f2-g2-a3-b3-c3-d3-e3-T2  (I)T3-g′0-a′1-b′1-c′1-d′1-e′1-f′1-g′1-a′2-b′2-c′2-d′2-e′2-f′2-g′2-a′3-b′3-c′3-d′3-e′3-f′3-T4  (II),as described in the present application. Methods of using these macrostructures are also disclosed.

In various aspects and embodiments, the invention provides a method of controlling at least one cellular process in a mammalian cell via self-assembly of a synthetic organelle from expression of a scaffold protein capable of undergoing liquid-liquid phase separation (LLPS) tagged with a coiled coil. The method also comprises inserting one or more coiled coil or dimerization tags into the genome of a target mammalian cell; tags are operatively linked to at least one cellular decision making protein, thereby forming a sequesterable construct upon scaffold expression and controlling at least one cellular process.

The invention relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of a primary hepatocellular carcinoma target-free drug and application of the combined marker, and the combined marker is a folate receptor gamma gene FOLR3 derived from peripheral blood leucocyte mRNA, a layered protein gene SFN and a coiled-coil domain protein 9 gene CCDC9. According to the invention, combined detection is carried out based on a plurality of peripheral blood leucocyte markers, and compared with a single molecular marker, errors caused by individual expression difference of a single index can be reduced to a certain extent, so that the detection result is more accurate. The curative effect prediction model constructed based on detection of peripheral blood leucocyte mRNA level change can perform specific recognition detection in the initial stage of tumor formation, has high sensitivity and high specificity, and provides an important means for reasonable medication of hepatocellular carcinoma patients sensitive or resistant to target-free drugs. The important significance is realized on the effective treatment of the hepatocellular carcinoma in China.

According to the present invention, the CCDC3 gene containing the coiled coil domain 3 (CCDC3) is related to the occurrence and the development of the breast cancer, and the CCDC3 gene containing the coiled coil domain 3 (CCDC3) is related to the occurrence and the development of the breast cancer; cCDC3 is a glycosylated secretory protein, is mainly expressed in vascular endothelial cells and mature adipocytes, has the function of regulating liver lipid metabolism, and plays a role in obesity and atherosclerosis processes in autosecretion, paracrine and endocrine modes. The recent research finds that compared with other tissues, the breast tissues have higher CCDC3mRNA expression, and the high-level CCDC3 in breast cancer patients is related to higher survival rate and lower recurrence rate. Further research finds that CCDC3 activates p53 in a positive feedback mode to inhibit growth of breast cancer cells. In order to further reveal the effect of the CCDC3 in breast cancer, in order to construct an RNAi lentiviral vector of the CCDC3 gene, breast cancer cells are infected in vitro, the CCDC3 gene in the cells is not expressed or is reduced in expression, and then the biological function of the cells is detected, so that the influence of the CCDC3 gene on the biological function of the breast cancer cells is analyzed.

To provide a multimer fusion protein, and a method for producing a multimer fusion protein.SOLUTION: A method according to the present invention includes: expressing a nucleic acid encoding an amino acid sequence which includes a signal peptide, (optionally) an antigenic peptide, a CH3 domain of a human IgG1, a (G-P-P)10 collagen-like domain, and a TNF ligand superfamily extracellular domain, from the N terminal to the C terminal, where the extracellular domain lacks a coiled coil trimerization motif, in a mammalian cell; and allowing the nucleic acid-derived polypeptide expressed in the mammalian cell to perform at least one of trimerization and hexamerization to be formed into one or more multimer fusion proteins.SELECTED DRAWING: None

Force-sensing peptides that can be used as sensor molecules or that can be used for signal transduction by detecting forces and converting the forces into biological signals, and methods of using the force-sensing peptides, are described. The force-sensing peptide comprises two alpha-helical domains linked by a linker sequence wherein the two alpha-helical domains form a coiled helical domain, referred to as a closed conformation, in the absence of an external force, and further wherein the two alpha-helical domains form a coiled helical domain, referred to as a closed conformation, in the presence of a force above the unhelicizing threshold level of the coiled helical domain. The coiled-coil domain undergoes a conformational change to an open conformation.

The present invention is directed to a method for treating primary ciliary dyskinesia (PCD) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 3 of the coiled-coil domain containing 40 (CCDC40) pre-mRNA. Also provided is a composition comprising the splicing modulator, and use of same.

The present invention relates to a lipopeptide building block, the lipid building block consisting of: (i) a peptide portion, the peptide portion comprising a coiled-coil peptide segment, wherein the coiled-coil peptide segment comprises 3 to 8 repeating units, and wherein the repeating units consist of the sequence IEKKIE-X0 (SEQ ID NO: 58), wherein X0 represents an amino acid, and wherein preferably the repeating units consist of a sequence selected from IEKKIEG (SEQ ID NO: 59), IEKKIEA (SEQ ID NO: 12) or IEKKIES (SEQ ID NO: 13), and wherein further preferably the repeating units consist of the sequence IEKKIES (SEQ ID NO: 13); (ii) a lipid portion, the lipid portion comprising or preferably consisting of formula LM-I, wherein R 1 and R 2 Independently C 11‑15 Alkyl, wherein preferably R 1 and R 2 Independently C 11 H 23 ,‑C 13 H 27 or ‑C 15 H 31 , and wherein further preferably R 1 and R 2 C 15 H 31 ; and where R 3 is hydrogen or ‑C(O)C 11‑15 alkyl, and wherein preferably R 3 H or ‑C(O)C 15 H 31 and wherein the lipid portion is linked to the peptide portion, wherein the wavy line in formula LM-I indicates the site of attachment to the peptide portion, and wherein preferably the lipid portion is linked to the N-terminus of the peptide portion, and the present invention relates to conjugates comprising the lipopeptide building block to which an antigen is coupled, bundles of such conjugates, synthetic virus-like particles (SVLPs) comprising a bundle of at least one conjugate, and pharmaceutical compositions comprising the conjugates. The present invention further relates to the conjugates, bundles of conjugates, the SVLPs and the pharmaceutical compositions for use as medicaments, as vaccines and in methods for preventing or treating diseases preferably selected from infectious diseases, allergies and cancer and generally for effectively inducing an antigen-specific immune response. #imgabs0#